Research programme: HBV cccDNA epigenetic modifiers - Arbutus Biopharma

Drug Profile

Research programme: HBV cccDNA epigenetic modifiers - Arbutus Biopharma

Alternative Names: cccDNA epigenetic modifiers - Arbutus Biopharma; Covalently closed circular DNA epigenetic modifiers - Arbutus Biopharma

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
  • Developer Arbutus Biopharma; Baruch S. Blumberg Institute
  • Class Antivirals; Small molecules
  • Mechanism of Action Genetic transcription modulators; Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
  • 03 Aug 2015 Tekmira Pharmaceuticals is now called Arbutus Biopharma
  • 11 Jan 2015 OnCore Biopharma has merged with Tekmira Pharmaceuticals Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top